Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*

Creative Commons License

Miyamoto T., Sanford D., Tomuleasa C., Hsiao H., Enciso Olivera L. J., Kumar Enjeti A., ...Daha Fazla

LEUKEMIA & LYMPHOMA, cilt.63, sa.4, ss.928-938, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/10428194.2021.2002321
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.928-938
  • Anahtar Kelimeler: Acute myeloid leukemia, hypomethylating agents, low-dose cytarabine, best supportive care, unfit patients, ACUTE MYELOID-LEUKEMIA, OLDER PATIENTS, ELDERLY-PATIENTS, SUPPORTIVE CARE, SURVIVAL, AZACITIDINE
  • Çukurova Üniversitesi Adresli: Evet

Özet

Acute myeloid leukemia (AML) predominantly affects the elderly, and prognosis declines with age. Induction chemotherapy plus consolidation therapy is standard of care for fit patients; options for unfit patients include hypomethylating agents (HMA), low-dose cytarabine (LDAC), targeted therapies, and best supportive care (BSC). This retrospective chart review evaluated clinical outcomes in unfit patients with AML who initiated first-line treatment or BSC 01/01/2015-12/31/2018. Overall survival (OS), progression-free survival (PFS), time-to-treatment failure (TTF), and response rates were assessed. Of 1762 patients, 1310 received systemic therapies: 809 HMA, 199 LDAC, and 302 other therapies; 452 received BSC. Median OS was 9.9, 7.9, 5.4, and 2.5 months for HMA, LDAC, other, and BSC, respectively. Median PFS was 7.5, 5.3, 4.1, and 2.1 months for HMA, LDAC, other, and BSC, respectively; median TTF was 4.9, 2.1, 2.2, and 2.1 months, respectively. Our findings highlight the unmet need for novel therapies for unfit patients.